Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05851287
Other study ID # 2023KYPJ003
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 20, 2023
Est. completion date February 19, 2029

Study information

Verified date April 2023
Source Zhongshan Ophthalmic Center, Sun Yat-sen University
Contact Xun Wang, M.D.
Phone +8615017541549
Email wangx48@mail2.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Aging is a major risk factor for many blind-causing eye diseases, e.g., glaucoma, age-related cataracts, and age-related macular degeneration. With the population aging, the impact of lifestyle changes (less time spent outdoors, increasingly sedentary lifestyles, and unhealthy eating habits) on the eye health of the elderly needs further research. This study focuses on establishing a cohort of elderly subjects with normal vision and ocular structure at baseline. The main goal is to study the risk factors for common eye diseases in Chinese elderly population while providing normal-controlled clinical and genomic data for other clinical studies on eye diseases.


Recruitment information / eligibility

Status Recruiting
Enrollment 2500
Est. completion date February 19, 2029
Est. primary completion date February 19, 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years to 95 Years
Eligibility Inclusion criteria: 1. Be able and willing to consent to the qualification and the follow-up phases of the study; 2. Be able to undergo yearly examinations for =5 years; 3. Age is older than 60 years; 4. Best-corrected visual acuity of both eyes is better than 20/32; 5. Intraocular pressure (non-contact tonometer) is between 10-21 mmHg; 6. Except for mild cataracts, no other structural abnormalities of the eye are found. 7. have fundus photographs of adequate quality as assessed with a standardized protocol by the University of Wisconsin Fundus Photograph Reading Center. Exclusion Criteria: 1. the presence of ocular disease in either eye, except for mild cataracts and ametropia; 2. previous retinal or other ocular surgical procedures (other than cataract extraction and capsulotomy); 3. a chronic requirement for any systemic or ocular medication administered for other diseases and known to be toxic to the retina or optic nerve; 4. cataract surgery within three months or capsulotomy within six weeks before the qualification visit; 5. any systemic disease with a poor 5-year survival prognosis.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Zhongshan Ophthalmic Center, Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Zhongshan Ophthalmic Center, Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of visual impairment at Year 1 The best corrected visual acuity is worse than 15/25. 1 Year
Primary The incidence of visual impairment at Year 2 The best corrected visual acuity is worse than 15/25. 2 Year
Primary The incidence of visual impairment at Year 3 The best corrected visual acuity is worse than 15/25. 3 Year
Primary The incidence of visual impairment at Year 4 The best corrected visual acuity is worse than 15/25. 4 Year
Primary The incidence of visual impairment at Year 5 The best corrected visual acuity is worse than 15/25. 5 Year
Secondary Change from Baseline Best Corrected Visual Acuity at 1 Year 1 Year
Secondary Change from Baseline Best Corrected Visual Acuity at 2 Year 2 Year
Secondary Change from Baseline Best Corrected Visual Acuity at 3 Year 3 Year
Secondary Change from Baseline Best Corrected Visual Acuity at 4 Year 4 Year
Secondary Change from Baseline Best Corrected Visual Acuity at 5 Year 5 Year
Secondary The incidence of age-related cataract at Year 1 Presence of moderate to severe cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII). 1 Year
Secondary The incidence of age-related cataract at Year 2 Presence of moderate to severe cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII). 1 Year
Secondary The incidence of age-related cataract at Year 3 Presence of moderate to severe cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII). 3 Year
Secondary The incidence of age-related cataract at Year 4 Presence of moderate to severe cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII). 4 Year
Secondary The incidence of age-related cataract at Year 5 Presence of moderate to severe cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII). 5 Year
Secondary The incidence of age-related macular degeneration at Year 1 The development of the neovascular form of AMD or the development of geographic atrophy that involves the center of the macula in one or both eyes. 1 Year
Secondary The incidence of age-related macular degeneration at Year 2 The development of the neovascular form of AMD or the development of geographic atrophy that involves the center of the macula in one or both eyes. 2 Year
Secondary The incidence of age-related macular degeneration at Year 3 The development of the neovascular form of AMD or the development of geographic atrophy that involves the center of the macula in one or both eyes. 3 Year
Secondary The incidence of age-related macular degeneration at Year 4 The development of the neovascular form of AMD or the development of geographic atrophy that involves the center of the macula in one or both eyes. 4 Year
Secondary The incidence of age-related macular degeneration at Year 5 The development of the neovascular form of AMD or the development of geographic atrophy that involves the center of the macula in one or both eyes. 5 Year
Secondary The incidence of glaucoma at Year 1 1 Year
Secondary The incidence of glaucoma at Year 2 2 Year
Secondary The incidence of glaucoma at Year 3 3 Year
Secondary The incidence of glaucoma at Year 4 4 Year
Secondary The incidence of glaucoma at Year 5 5 Year
Secondary The incidence of diabetic retinopathy at Year 1 1 Year
Secondary The incidence of diabetic retinopathy at Year 2 2 Year
Secondary The incidence of diabetic retinopathy at Year 3 3 Year
Secondary The incidence of diabetic retinopathy at Year 4 4 Year
Secondary The incidence of diabetic retinopathy at Year 5 5 Year
Secondary The incidence of myopia-related fundus changes at Year 1 1 Year
Secondary The incidence of myopia-related fundus changes at Year 2 2 Year
Secondary The incidence of myopia-related fundus changes at Year 3 3 Year
Secondary The incidence of myopia-related fundus changes at Year 4 4 Year
Secondary The incidence of myopia-related fundus changes at Year 5 5 Year
Secondary Change from Baseline Self-scoring of the Visual Quality assessment scale at Year 1 Self-assessment of the visual quality will be evaluated by Visual Function index-14 (Chinese version) Questionnaire, higher scores mean a worse outcome. 1 Year
Secondary Change from Baseline Self-scoring of the Visual Quality assessment scale at Year 2 Self-assessment of the visual quality will be evaluated by Visual Function index-14 (Chinese version) Questionnaire, higher scores mean a worse outcome. 2 Year
Secondary Change from Baseline Self-scoring of the Visual Quality assessment scale at Year 3 Self-assessment of the visual quality will be evaluated by Visual Function index-14 (Chinese version) Questionnaire, higher scores mean a worse outcome. 3 Year
Secondary Change from Baseline Self-scoring of the Visual Quality assessment scale at Year 4 Self-assessment of the visual quality will be evaluated by Visual Function index-14 (Chinese version) Questionnaire, higher scores mean a worse outcome. 4 Year
Secondary Change from Baseline Self-scoring of the Visual Quality assessment scale at Year 5 Self-assessment of the visual quality will be evaluated by Visual Function index-14 (Chinese version) Questionnaire, higher scores mean a worse outcome. 5 Year
Secondary Change from Baseline Self-scoring of the Quality of Life at Year 1 Self-assessment of the life quality will be evaluated by EQ-5D questionnaires, lowerer scores mean a worse outcome. 1 Year
Secondary Change from Baseline Self-scoring of the Quality of Life at Year 2 Self-assessment of the life quality will be evaluated by EQ-5D questionnaires, lowerer scores mean a worse outcome. 2 Year
Secondary Change from Baseline Self-scoring of the Quality of Life at Year 3 Self-assessment of the life quality will be evaluated by EQ-5D questionnaires, lowerer scores mean a worse outcome. 3 Year
Secondary Change from Baseline Self-scoring of the Quality of Life at Year 4 Self-assessment of the life quality will be evaluated by EQ-5D questionnaires, lowerer scores mean a worse outcome. 4 Year
Secondary Change from Baseline Self-scoring of the Quality of Life at Year 5 Self-assessment of the life quality will be evaluated by EQ-5D questionnaires, lowerer scores mean a worse outcome. 5 Year
See also
  Status Clinical Trial Phase
Recruiting NCT05414994 - Assessment of the Ocular Microbiome in Health and Disease
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Completed NCT02811692 - Study for Collection of Aflibercept Data in Routine Practice
Recruiting NCT06045299 - Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia Phase 3
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT04799704 - Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
Recruiting NCT05876689 - Swept Source OCT Imaging With the DREAM VG-OCT
Active, not recruiting NCT04123626 - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene Phase 1/Phase 2
Recruiting NCT04150432 - Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children N/A
Not yet recruiting NCT05550740 - Repeated Low-Level Red-Light Therapy for Shortening Axial Length N/A
Completed NCT02332343 - Sparing of the Fovea in Geographic Atrophy Progression N/A
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Terminated NCT01225146 - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Phase 1
Completed NCT00333203 - Next Generation Ophthalmic Irrigating Solution Posterior Segment Study Phase 3
Not yet recruiting NCT05565547 - Multimodal Equipment for Teleophthalmology Assessment (META)
Recruiting NCT05158699 - Effectiveness of Periocular Drug Injection in CATaract Surgery Phase 3
Recruiting NCT06451172 - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis Early Phase 1
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Completed NCT05211089 - Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
Not yet recruiting NCT06070467 - Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases